Sarepta Therapeutics, Inc. (SRPT) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Sarepta Therapeutics, Inc. (SRPT): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 48/100 — a percentile rank of Sarepta Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $1.9B |
| P / S | 0.9× |
| EV / EBITDA | -121.6× |
| Gross margin | 59.1% |
| Operating margin | -7.3% |
| Net margin | -6.9% |
| Return on equity | -8.9% |
| ROIC | -8.3% |
| Revenue growth | -20.4% |
| Debt / equity | 0.6× |
| Dividend yield | 0.0% |
Is Sarepta Therapeutics, Inc. overvalued? P/S looks undervalued vs its 5-year range; P/B looks undervalued vs its 5-year range.
Independent of the events above — derived from Sarepta Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact